Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 8 September 2017, 11:32 HKT/SGT
Share:
    

Source: Eisai
Conclusion of Development Collaboration Agreement for Lenvima (Lenvatinib Mesylate) and Opdivo (Nivolumab) Combination Therapy for Treatment of Hepatocellular Carcinoma

TOKYO, Sept 8, 2017 - (JCN Newswire) - Eisai Co., Ltd. and Ono Pharmaceutical Co., Ltd. have announced that they have entered into a collaboration agreement to jointly develop the combination therapy of Eisai's multi-kinase inhibitor, Lenvima (lenvatinib mesylate) and Ono's human anti-human PD-1 (programmed cell death-1) monoclonal antibody, Opdivo (nivolumab) for the treatment of hepatocellular carcinoma (HCC) .

Based on this agreement, Eisai and Ono will swiftly implement a Phase Ib clinical trial in Japan to investigate the safety, tolerability, and efficacy of the combination of Lenvima and Opdivo in patients with HCC. Details relating to the financial and other conditions of this agreement are confidential.

Liver cancer is the second most common cause of cancer related deaths, with an estimated 750,000 deaths per year globally.(1) Additionally, 780,000 cases are newly diagnosed each year, about 80% of which occur in Asian regions, including Japan and China.(1) HCC accounts for approximately 85% to 90% of liver cancer cases. It is estimated that there are approximately 42,000 HCC patients in Japan,2 with 26,000 deaths per year.(3) Treatment options for unresectable HCC are limited and the prognosis is very poor, so this remains an area with high unmet medical needs. Eisai submitted an application for an additional indication of Lenvima for the treatment of HCC in Japan in June 2017. Ono is currently conducting a Phase III clinical trial of Opdivo for the treatment of HCC in Japan.

Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer, Oncology Business Group, Eisai, commented, "Our non-clinical research has demonstrated synergistic antitumor activities in the Lenvima and anti-PD1 antibody combination, which are considered to be a result of an immunostimulatory response through a reduction in immunosuppressive tumor-associated macrophages and an increase in cytotoxic T lymphocytes by Lenvima. Through the development of a combination therapy that has the potential to produce synergistic effects between Lenvima and nivolumab, both drugs of Japanese origin, we anticipate being able to further contribute to addressing the high unmet medical needs of HCC patients and their families and improving their benefits."

Hiroshi Awata, Vice President Executive Officer / Executive Director, Clinical Development, Ono, commented, "We have been actively engaged in the development of Opdivo not only in monotherapy, but combination therapies with other agents. As we believe that the combination therapy may exert more excellent therapeutic efficacy compared to the monotherapy, we are very pleased to pursue the potential for developing the combination therapy of Opdivo with lenvatinib. We expect that the combination therapy with Opdivo and lenvatinib will be a new treatment option for the patients with hepatocellular carcinoma."

About Lenvima (lenvatinib mesylate)

Discovered and developed in-house, lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFRalpha; KIT; and RET) involved in tumor proliferation. Currently, Eisai has obtained approval for lenvatinib as a treatment for refractory thyroid cancer in over 50 countries, including the United States, Japan, and in Europe. Additionally, Eisai has obtained approval for the agent in combination with everolimus as a treatment for renal cell carcinoma (second-line) in over 35 countries, including the United States and in Europe. In Europe, the agent was launched under the brand name Kisplyx for renal cell carcinoma. The submission of applications in Japan (June 2017), the United States and Europe (July 2017), Eisai also plans to submit an application for lenvatinib for the treatment of HCC in China within the latter half of fiscal 2017. Furthermore, a Phase III study of lenvatinib in separate combinations with everolimus and pembrolizumab in renal cell carcinoma (first-line) was initiated and is underway. A Phase Ib/II study to investigate the agent in combination with pembrolizumab in select solid tumors (non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, head and neck cancer, and melanoma) and a Phase Ib study in HCC are also underway.

About Opdivo (nivolumab)

Opdivo is a PD-1 immune checkpoint inhibitor that uses the body's immune system to help restore antitumor immune response. In Japan, Ono launched Opdivo for the treatment of unresectable melanoma in September 2014. Ono received an approval for additional indication of unresectable, advanced or recurrent non-small cell lung cancer in December 2015, unresectable or metastatic renal cell cancer in August 2016, relapsed or refractory classical Hodgkin lymphoma in December 2016 and recurrent or metastatic head and neck cancer in March 2017. In addition, ONO has submitted supplemental application for additional indication of gastric cancer, and is conducting clinical development program including esophageal cancer, gastro-esophageal junction cancer, small cell lung cancer, hepatocellular carcinoma, glioblastoma, urothelial cancer, malignant pleural mesothelioma, ovarian cancer, biliary tract cancer, etc. Opdivo is currently approved in more than 60 countries, including the US, Europe, South Korea and Taiwan.

(1) GLOBOCAN2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/
(2) Ministry of Health, Labour and Welfare, 2014 Patient Survey 3 Ministry of Health, Labour and Welfare, 2014 Population Trends Survey

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific fields. It focuses especially on oncology and diabetes. For further information., please visit the company's website at http://www.ono.co.jp/eng/.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Sept 8, 2017 11:32 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Sept 22, 2017 15:46 HKT/SGT
Eisa: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
Sept 22, 2017 09:56 HKT/SGT
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC
Sept 19, 2017 09:01 HKT/SGT
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference
Sept 13, 2017 13:25 HKT/SGT
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
Sept 12, 2017 23:06 HKT/SGT
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out
Sept 12, 2017 22:37 HKT/SGT
Eisai Selected for Fifth Consecutive Year of Membership in Dow Jones Sustainability Asia Pacific Index 2017
Sept 12, 2017 22:18 HKT/SGT
Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress
Sept 12, 2017 21:54 HKT/SGT
Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima (Lenvatinib) in Combination with Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress
Sept 6, 2017 15:35 HKT/SGT
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Combination Study for Lenvima (Lenvatinib) and Pembrolizumab Due to Encouraging Initial Data in Endometrial Carcinoma
Sept 6, 2017 13:52 HKT/SGT
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Study for Halaven (Eribulin) and Pembrolizumab Combination Due to Encouraging Initial Data in Triple-Negative Breast Cancer
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: